Treatment options for recurrent pancreatic cancer are as varied as the disease itself. Gemcitabine, an anti-cancer drug, and olaparib are among the most common treatments. ERCP, a surgical procedure for pancreatic cancer that uses a camera to look at the organ's functions, is also an option. But which type is best for you? Let's find out!
Gemcitabine is recommended for metastatic pancreatic cancer.
For advanced pancreatic cancer, gemcitabine is considered a standard of care. It has shown promising results in improving the overall survival and clinical benefit of patients with progressive disease. However, gemcitabine-based chemotherapy regimens have only been tested on patients with good performance status and few comorbidities. In recent years, nab-paclitaxel and gemcitabine have also been studied in combination with other drugs.
While most types of pancreatic cancer are initially treated in the pancreas, they may spread to distant organs. For example, pancreatic cancer may apply to the lungs or bone. The treatment for recurrent pancreatic cancer usually involves chemotherapy drugs. Targeted therapy may also be used. In advanced cases, immunotherapy can be a helpful treatment. Additionally, radiation therapy and stent placement may be used to alleviate symptoms.
Olaparib is a drug for metastatic pancreatic cancer
The most common adverse events (AEs) of Olaparib were nausea, vomiting, decreased appetite, anemia, and respiratory tract infection. AEs were grade 3 or higher and were recurrent in approximately 25% of patients. Olaparib was also associated with rare but severe side effects, including arthralgia. Olaparib is currently not approved for use in patients with advanced pancreatic cancer.
A study of the PARP inhibitor olaparib showed that patients with advanced pancreatic cancer with germline BRCA mutations were less likely to die. However, platinum-based chemotherapy has many side effects, and the longer patients take it, the worse they become. That's why many patients choose to use PARP inhibitors as maintenance therapy, which is given to slow the progression of the disease and maintain a quality of life. Unfortunately, no such maintenance therapy exists for advanced pancreatic cancer.
ERCP is a treatment option for metastatic pancreatic cancer
An ERCP can be a treatment option for metastatic pancreas cancer. The procedure is a combination of several steps. First, it can be used to perform a biopsy and stent placement and examine the pancreatic ducts. The results of the ERCP procedure are available within a few days. However, a sore throat is expected after the procedure.
An ERCP involves using an endoscope to visualize bile ducts. Bile ducts can be obstructed by pancreatic cancer, causing jaundice. A thin, lighted tube called an endoscope is inserted through the vents. A dye is injected into the ducts, showing if the pancreas has spread. The endoscope can also be used to insert a fine tube to unblock the ducts.
Treatment options for recurrent pancreatic cancer
Treatment options for recurrent pancreatic carcinomas are often based on the type of tumor. Borderline resectable pancreatic cancer, which has spread to a nearby blood vessel or tissue, can be removed via surgery. Localized advanced pancreatic cancer, in which cancer has spread to nearby organs or lymph nodes, is considered metastatic. In cases of recurrent pancreatic cancer, cancer has returned to other parts of the body. While the exact causes of the recurrence of pancreatic cancer are unknown, several common treatments are available for patients with this type of cancer.
Treatment for recurrent pancreatic cancer depends on the location and type of cancer. The type of chemotherapy will depend on which drugs were used to treat the original tumor. Treatment may also include palliative surgeries. The goal of treatment is to reduce symptoms and prolong the patient's life. The primary purpose of recurrent pancreatic cancer is to control its recurrence. This means that a patient will be given palliative care to deal with the effects of cancer.